<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01151722</url>
  </required_header>
  <id_info>
    <org_study_id>HCRP22</org_study_id>
    <nct_id>NCT01151722</nct_id>
  </id_info>
  <brief_title>Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage</brief_title>
  <acronym>ABeVi</acronym>
  <official_title>Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Diabetic Vitreous Hemorrhage</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Postoperative vitreous hemorrhage is a common complication after vitrectomy for proliferative
      diabetic retinopathy. There have been efforts to lower the incidence of postoperative
      vitreous hemorrhage such as preoperative bevacizumab injection. Bevacizumab (Avastin) is a
      potent inhibitor of angiogenesis and has been shown to decrease retinal and iris
      neovascularization in proliferative diabetic retinopathy. Recently there have been reports
      showing that preoperative bevacizumab injection could reduce intraoperative bleeding from
      abnormal vessels and could make surgery easier and more successful. Our hypothesis is that
      intraoperative bevacizumab injection could reduce postoperative vitreous hemorrhage by
      inhibiting the vessel formation after surgery.

      We started the prospective randomized comparative study to determine the effect of pre and
      intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic
      vitrectomy in comparison to vitrectomy without any adjuvant drug.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2009</start_date>
  <primary_completion_date type="Anticipated">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vitreous hemorrhage recurrence</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Recurrent</condition>
  <condition>Hemorrhage</condition>
  <arm_group>
    <arm_group_label>no injection</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no bevacizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab before vitrectomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>experimental 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bevacizumab after vitrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bevacizumab injection</intervention_name>
    <description>bevacizumab injection before vitrectomy</description>
    <arm_group_label>experimental 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bevacizumab injection</intervention_name>
    <description>bevacizumab injection after vitrectomy</description>
    <arm_group_label>experimental 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing first vitrectomy for vitreous hemorrhage secondary to
             proliferative diabetic retinopathy

        Exclusion Criteria:

          -  follow-up period of less than 3 months

          -  not first vitrectomy

          -  abnormal blood coagulation

          -  uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Felipe Almeida</last_name>
    <email>felipeppalmeida@yahoo.com.br</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital das Clínicas de Ribeirão Preto - University of São Paulo</name>
      <address>
        <city>Ribeirão Preto</city>
        <state>Sao Paulo</state>
        <zip>14049-990</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Felipe Almeida, MD</last_name>
      <phone>16 3602-2523</phone>
      <phone_ext>2523</phone_ext>
      <email>felipeppalmeida@yahoo.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Felipe Almeida</last_name>
    </contact_backup>
    <investigator>
      <last_name>Felipe Almeida, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2010</study_first_submitted>
  <study_first_submitted_qc>June 25, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2010</study_first_posted>
  <last_update_submitted>June 25, 2010</last_update_submitted>
  <last_update_submitted_qc>June 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 28, 2010</last_update_posted>
  <responsible_party>
    <name_title>USP</name_title>
    <organization>USP</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Vitreous Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

